Severe Acute Respiratory Syndrome

Potential SARS treatment to be developed by MBL and partner

Published in Vaccine Weekly, May 21st, 2003

Medarex, Inc., (MEDX) and the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School announced that they have entered into an agreement by which they intend to codevelop fully human antibodies to severe acute respiratory syndrome (SARS).

The parties plan to use Medarex's UltiMAb technology to generate fully human antibodies to SARS.

Under the terms of the agreement, Medarex and MBL expect to share equally the development costs of any antibody products as well as any future revenues arising from these products.

"We believe that development of a fully human neutralizing antibody to the SARS virus...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-05-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry